Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

NW Bio releases promising new data on DCVax-Direct Phase I trial for inoperable solid tumors

NW Bio releases promising new data on DCVax-Direct Phase I trial for inoperable solid tumors

Veritas Genetics introduces genetic screen for hereditary breast and ovarian cancer risk

Veritas Genetics introduces genetic screen for hereditary breast and ovarian cancer risk

VBL Therapeutics reports positive results from VB-111 Phase 1/2a study in recurrent platinum-resistant Müllerian cancer

VBL Therapeutics reports positive results from VB-111 Phase 1/2a study in recurrent platinum-resistant Müllerian cancer

Adaptimmune presents clinical results of NY-ESO TCR therapeutic candidate at ASCO 2015

Adaptimmune presents clinical results of NY-ESO TCR therapeutic candidate at ASCO 2015

Trabectedin may be better than dacarbazine for treatment of soft tissue sarcoma

Trabectedin may be better than dacarbazine for treatment of soft tissue sarcoma

Invitae introduces new patient pay program to make genetic testing more affordable, accessible

Invitae introduces new patient pay program to make genetic testing more affordable, accessible

Esperance announces positive results from EP-100 Phase II trial in paclitaxel-resistant ovarian cancer

Esperance announces positive results from EP-100 Phase II trial in paclitaxel-resistant ovarian cancer

ASCO 2015: UH Seidman Cancer Center researchers present data from several new studies

ASCO 2015: UH Seidman Cancer Center researchers present data from several new studies

Two grants to bolster research on why ovarian cancer is resistant to chemotherapy

Two grants to bolster research on why ovarian cancer is resistant to chemotherapy

New clinical studies on Myriad Genetics myChoice HRD companion diagnostic test presented at ASCO 2015

New clinical studies on Myriad Genetics myChoice HRD companion diagnostic test presented at ASCO 2015

Cancer genetic counselor helps patients make sense of genetics and statistics

Cancer genetic counselor helps patients make sense of genetics and statistics

Penn researchers to present clinical data at 2015 ASCO Annual Meeting

Penn researchers to present clinical data at 2015 ASCO Annual Meeting

B Floral raises awareness for Ovarian Cancer Research Fund

B Floral raises awareness for Ovarian Cancer Research Fund

Myriad Genetics announces new clinical studies on myChoice HRD companion diagnostic test at ASCO 2015

Myriad Genetics announces new clinical studies on myChoice HRD companion diagnostic test at ASCO 2015

Larger studies needed to validate multigene testing for prediction of breast cancer risk

Larger studies needed to validate multigene testing for prediction of breast cancer risk

Array BioPharma presents clinical data of BRAF, MEK and HER2 drugs at 2015 ASCO Annual Meeting

Array BioPharma presents clinical data of BRAF, MEK and HER2 drugs at 2015 ASCO Annual Meeting

DNA analysis reveals how ovarian cancer takes genetic twists and turns to outsmart chemotherapy

DNA analysis reveals how ovarian cancer takes genetic twists and turns to outsmart chemotherapy

Researchers identify six mRNA isoforms that could be used to diagnose early-stage ovarian cancer

Researchers identify six mRNA isoforms that could be used to diagnose early-stage ovarian cancer

Clinical genomic sequencing could impact treatment decisions in advanced prostate cancer patients

Clinical genomic sequencing could impact treatment decisions in advanced prostate cancer patients

Non-coding micro RNA molecule may control chemotherapy resistance among ovarian cancer patients

Non-coding micro RNA molecule may control chemotherapy resistance among ovarian cancer patients

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.